AI can reduce frequency of adverse drug events, research suggests

The results of a recent study suggest that artificial intelligence (AI) can be harnessed to prevent or mitigate the effects of adverse drug events (ADRs). The study was published in “The Lancet Digital Health Journal”.

The review authors described the use of AI to reduce the frequency of ADEs as an emerging area of ​​study and identified several use cases where AI could help reduce or prevent ADEs. Moreover, genetic information is considered essential to improve the performance of AI algorithms. With the prevalence of genotyping, researchers are confident that this type of data can be more accessible over time and ultimately used to improve the functioning of AI algorithms and patient health.

“One of our challenges is how to identify and select the most relevant genetic variables from large amounts of genetic profile information,” said lead author Ania Syrowatka, Ph.D., of the Division general internal medicine and primary care. “Through this article, we wanted to present a review of how AI could be used to prevent unwanted side effects, and in the process we learned that we are still in the early stages of development and implementation. Systematic and comprehensive evaluations of these types of tools in prospective trials are needed to generate the evidence to move this field forward in a transparent, safe and effective manner,” added Syrowatka.

(This story has not been edited by the Devdiscourse team and is auto-generated from a syndicated feed.)

Comments are closed.